Safety and Tolerability of MSI-1436C in Metastatic Breast Cancer
Status:
Terminated
Trial end date:
2018-05-14
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, dose escalation study. MSI-1436 will be administered as a
single intravenous infusion twice a week for 3 weeks on a 4-week cycle.